Active Targeted Drug Delivery for Microbes Using Nano-Carriers

Yung-Sheng Lin¹, Ming-Yuan Lee¹, Chih-Hui Yang² and Keng-Shiang Huang³*

¹Department of Chemical Engineering, National United University, Miaoli, Taiwan; ²Department of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan; ³The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan

Abstract: Although vaccines and antibiotics could kill or inhibit microbes, many infectious diseases remain difficult to treat because of acquired resistance and adverse side effects. Nano-carriers-based technology has made significant progress for a long time and is introducing a new paradigm in drug delivery. However, it still has some challenges like lack of specificity toward targeting the infectious site. Nano-carriers utilized targeting ligands on their surface called ‘active target’ provide the promising way to solve the problems like accelerating drug delivery to infectious areas and preventing toxicity or side-effects. In this mini review, we demonstrate the recent studies using the active targeted strategy to kill or inhibit microbes. The four common nano-carriers (e.g. liposomes, nanoparticles, dendrimers and carbon nanotubes) delivering encapsulated drugs are introduced.

Keywords: Active target, Ligands, Microbe, Nano-carrier.

1. INTRODUCTION

In modern life, human are always threaten by infectious diseases [1-6]. Bacteria, virus and fungi are the critical reasons to infectious diseases [7-11]. Bacteria served many diseases by the food route [12]. In Germany, Escherichia coli in Fenugreek sprouts exported from Egypt caused 48 deaths from 2011 to 2012 [13]. Virus could cause various diseases including human immunodeficiency virus (HIV) [14, 15] and influenza [16, 17]. Fungi like Cryptococcus neoformans could lead to chronic liver disease [18]. Luckily, with the development of safe vaccines and antibiotics, the infectious diseases seemed to be totally cured by these therapies [19]. However, there are some adverse drug effects if patients take these drugs at common dose or overdose such as insomnia [20], osteoporosis [21], headache [22] and liver failure [23]. Furthermore, these pathogens with a very fast doubling cycle develop a mechanism for becoming resistant to a specific drug at a glance [24]. In hence, scientists are trying to find new approaches to solve aforementioned problem urgently.

The nanotechnology is an emerging science [25, 26] and the nano-carriers have been used for medical applications for a long time [27-34]. Nano-carriers containing drug have emerged as an innovative and promising alternative for drug delivery to the targeted site [35]. They also greatly improve free drug safety and drug efficacy [36]. Drug-laden nano-carriers could be designed and tailored to reach the intended site. Thus, the pathogenic area could be precisely cured by the drug, elevating the therapeutic effectiveness [37]. There is a lot of significant proof that nano-carriers are superior in biocompatibility, targeting, and tissue penetration [38].

Compared to a free drug, the advantages of a nano-scale drug delivery system include increasing bioavailability, reduced drug amount and frequency and reduced systemic side effects [39]. In hence, active targeted drug delivery combined nano-technological carrier platforms is a better way to prolong, localize, target with the pathogenic sites and reduction of drug side-effects [40].

2. ACTIVE TARGETING STRATEGIES

One of the important prerequisites of a drug delivery system is to send a therapeutic agent effectively to the pathologic site as soon as it can [41]. Active targeted strategy is the prospective approach for drug delivery [32, 40]. Active strategies have introduced by Paul Ehrlich and known for ‘magic bullet’ to describe this system [42]. This system can reach the intended site in higher concentrations in the short period of time. Active targeted delivery is believed that it can improve efficacy while reducing unpleased side-effects. Some certain bacteria, fungi and all viruses are intracellular parasites [43]. As they are growing and reproducing inside the special host cells, scientists could create an active targeted drug delivery system that copied cells infected by those parasites [44]. Active targeted strategies used curtained ligands such as antibodies, peptides, nano-bodies, sugar molecules and aptamers on surface of nano-carriers to improve therapeutic efficaciy [45, 46]. Most common seen nano-carriers are liposomes [47-51], nanoparticles [52-56], dendrimers [57-59] and carbon nanotubes [60-62], and the others..

3. ACTIVE TARGETED NANO-CARRIERS

3.1. Liposomes

Liposomes are self-assembling spherical vesicles composed of amphiphilic lipid bilayers with an inner aqueous
core frequently used as platforms in pharmaceuticals and cosmetics for drug release [63-65]. This unique dual release capability makes the delivery of two types of substances in the same time [66]. The first FDA-approved liposomal drug, doxorubicin-encapsulated PEGylated liposomes for curing AIDS connected Kaposi’s sarcoma, begun production in 1995 [67]. Composed of natural lipids, liposomes are low toxicity, ease of preparation and high biodegradability [68]. In hence, it works well with a wide range of agents to facilitate a targeted delivery by means of abovementioned characteristics from liposomes [69]. Liposomes binding different specific ligands on their surface such as glycolipids of Archaea (Archaeosomes) or virus glycoprotein/antigens (virosomes) could display immunoadjuvant potential for a vaccine and higher affinity to the targeted sites than the free drug [66]. The details of references connected with binding ligands for treatment of diseases resulted from microbes are summarized in (Table 1).

### 3.2. Nanoparticles

Nanoparticles including metal and non-metal nanoparticle were systematized by our previous review [80]. Both of them have many unique physicochemical properties including extremely small size [81, 82], huge surface to mass ratio [83], high reactivity and a distinctive interaction with biological systems [84]. Nanoparticles have been demonstrated to elevate drug stability, bioavailability, targeting and uptake [85]. Particles less than 5 nm are rapidly expelled from the circulation by extravasation and larger particles have limited diffusion in the extracellular space [86]. In hence, the development of nanoparticles containing medicines has made it possible to increase the therapeutic index of many components using suited ligand to arrive the intention site [87]. Nanoparticles binding ligands could enhance antiviral activity and improve cytotoxicity, low water solubility, and rapid clearance from circulation of the free drug [88]. The details of studies to treat microbes by nanoparticles with binding ligands are summarized in (Table 2).

### 3.3. Dendrimers

Dendrimers were synthesized by Buhleier et al. and Tomalia et al. during 1970–1990 [96]. Dendrimers are synthetic, highly branched, spherical polymers [97, 98]. Compared to traditional linear polymers, dendrimers are much superior as a drug carrier [99]. Also, they have different kinds of dendrimers; polyamidoamine dendrimer is the first one to be created [80]. There are many outstanding properties of dendrimers such as monodispersity, nano-sizes and shapes, biocompatibility, low toxicity, good pharmacokinetics and can easily provide the active targeted drug delivery [96]. Dendrimers binding ligands result in reducing cytotoxicity, hemolytic bioactives and increasing biocompatibility than the free drug [96]. The details of references related to binding ligands to treat diseases caused by microbes are summarized in (Table 3).

### 3.4. Carbon Nanotubes

Carbon nanotubes are cylindrical nanostructures consisted of pure carbon atoms covalently bonded in hexagonal arrays [108]. They have two kinds of nanotube such as single-walled carbon nanotubes or multi-walled carbon nanotubes [109]. Carbon nanotubes showed the efficacy as drug delivery vehicles since they can be easily internalized into cells [110]. Moreover, single-walled carbon nanotubes have

| Ligands                                    | Target                  | Remarks                                      | Ref.  |
|--------------------------------------------|-------------------------|----------------------------------------------|-------|
| Human monoclonal single chain antibodies   | H5N1                    | 10 times reduction in the viral titer        | [70]  |
| T. cruzi protein antigens                  | T. cruzi                | All infected animals were survived after 30 days. | [71]  |
| Toll-like receptor 4                       | Respiratory syncytial virus | Decreasing lung viral titers upon live virus challenge in mice | [72]  |
| MPER-specific antibody 10E8                | HIV-1 (envelope glycoprotein gp41) | Constructing mimicking the fusion intermediate of gp41 | [73]  |
| MPER-specific single chain antibody, 2H10  | HIV-1 (envelope glycoprotein) | Preventing HIV-1 from infecting cells | [74]  |
| Wheat germ agglutinin                      | MRSA                    | Eradicating all MRSA at 1.25 μM (90 min)    | [75]  |
| Hepatitis A antigens                       | Hepatitis A virus       | Achieving 100% seroprotection in infants and children | [76]  |
| HA                                         | B-strain influenza      | Providing good immunogenicity, safety and tolerability on children | [77]  |
| HA                                         | A-strain Influenza      | Preventing 75% of influenza-like illnesses   | [78]  |
| Sendai virus F protein                     | Hepatitis C virus       | Inhibiting the Hepatitis C virus RNA functions. | [79]  |

*T. cruzi: Trypanosoma cruzi; MPER: Membrane-proximal external region; MRSA: Methicillin-resistant Staphylococcus aureus; HA: Hemagglutinin antigens; HIV: Human immunodeficiency virus*
Table 2. Nanoparticles biding ligands for microbes.

| Ligands                          | Target                    | Remarks                                                                 | Ref.   |
|---------------------------------|---------------------------|-------------------------------------------------------------------------|--------|
| CD4-BP4 peptide                 | HIV-2                     | Providing selective binding and efficient delivery of Indinavir to CD4+HIV host cells | [89]   |
| Ulex europaeus agglutinin I     | *S. aureus*               | Promoting clearance of an acute *S. aureus* systemic infection          | [90]   |
| Nucleic acid                    | HBV                       | Halting HBV replication                                                 | [91]   |
| Bacitracin A and Polymyxin E    | *S. aureus, B. amyloliquefaciens, E. coli* and *P. aeruginosa* | Resulting in up to 10-fold antibacterial activity and no bacterial resistance | [92]   |
| Polyoxometalate and tyrosine    | *E. coli*                 | Causing pore formation, cell wall cleavage and cell lysis of *E. coli*  | [93]   |
| HPV protein                     | HPV                       | Reducing HPV-related disease including cervical cancer                   | [94]   |
| Cell-penetrating peptides       | HPV                       | Providing 8 times cellular uptake                                       | [95]   |
| Integrin-binding peptide        | HBV                       | Delivering siRNA to the cytosol of the targeted cells                   | [88]   |

*S. aureus: Staphylococcus aureus; B. amyloliquefaciens: Bacillus amyloliquefaciens; E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa; HBV: Human papilloma virus; *HPV: Human papilloma virus

Table 3. Dendrimers biding ligands for microbes.

| Ligands                          | Target                    | Remarks                                                      | Ref.   |
|---------------------------------|---------------------------|--------------------------------------------------------------|--------|
| DC-SIGN lectin receptor         | HIV(P24 capsid protein)   | Reducing the infection by 100% at 10 μM                      | [100, 101] |
| SB105-A10 peptide               | HIV(Gp41 and gp120 envelope protein) | Inhibiting the HIV-1<sub>ada</sub> R5 strain infection without altering the tissue viability | [102]   |
| Anti-HIV nucleic acids          | HIV                       | Having 10 times less cytotoxic                               | [103]   |
| GaLAg2 tripeptides              | *P. aeruginosa*           | Inducing biofilm dispersal *in vitro*                        | [104]   |
| G2KPY tripeptide                | *P. aeruginosa*           | Inhibiting *P. aeruginosa* biofilm *in vitro*                | [105]   |
| SB105 and SB105 A10 peptides    | Human cytomegalovirus     | Enhancing antiviral activity                                 | [106]   |
| Gatifloxacin                    | MRSA                      | Increasing antimicrobial activity                             | [106]   |
| (RW)4D peptides                 | *E. coli*                 | Inhibiting biofilm formation of *E. coli*                    | [107]   |

*HIV: Human immunodeficiency virus; MRSA: Methicillin-resistant Staphylococcus aureus; E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa

high chemical stability and easy functionalization than multiwalled carbon nanotubes [80]. Single-atomic layer walled carbon nanotubes through surface modification have been continuously used in active targeted drug delivery [111]. Because of its large surface area, they have been bound numerous ligands on their surface to the targeted sites [111]. Although the carbon nanotubes are widely used for treatments of cancer, they are still few publications used in curing diseases caused by microbes. Compared to the free drug, carbon nanotubes binding different ligands provide promising outcomes like reducing adverse effects, controlling drug delivery and improving patient compliance [112]. The details of references associated with binding ligands to inhibit microbes are summarized in (Table 4).

4. CHALLENGES AND FUTURE DEVELOPMENTS

Although the active targeted strategy using nano-carriers has been solved many concerns from the conventional drug strategy, there is still a challenge reported by some researches [117]. Active targeted strategy was a notable and efficient approach to send drug toward the pathogenic organs, however, Kunjachan et al. reported active targeted strategy should not be overestimated because the drug retention time using the active targeted approach would be diminished easily in the animal model [46]. Besides, active targeted delivery needs highly specific target recognition and great deal of target binding affinity. In hence, length of branches carrying a ligand and the number of ligands per
nano-carriers should be considered [112]. Besides, the most of papers about active targeted drug delivery for microbes we collected are in vitro, scientists could further use in vivo model to determine the efficacy of active targeted strategy in the future.

**CONCLUSION**

Because of the site specific targeting of drugs and lots of other advantages, active targeted drug delivery system is gaining popularity in present scenario. By specific targeted ligands, drugs can be directly targeted to their site of action to prevent toxicity and undesired effects to other sites. These can be used for bioavailability enhancement of the drugs, having poor bioavailability, to reduce the dose of drug administered. Consequently, active targeted drug delivery using nano-carriers provide a guarantee to cure infectious diseases precisely and efficiently.

**CONFLICT OF INTEREST**

The authors confirm that this article content has no conflict of interest.

**ACKNOWLEDGEMENTS**

This work was financially supported by a grant from the Ministry of Science and Technology, Taiwan. (NSC 102-2632-B-241-001-MY3).

**REFERENCES**

1. McMichael, A.J. Globalization, climate change, and human health. N. Engl. J. Med., 2013, 368, 1335-1343.
2. Bhutta, Z.A.; Black, R.E. Global maternal, newborn, and child health - so near and yet so far. N. Engl. J. Med., 2013, 369, 2226-2235.
3. Assiri, A.; McGeer, A.; Perl, T.M.; Price, C.S.; Al Rabeeah, A.A.; Ou, K.L.; Huang, K.S.; Chifiriuc, M.C. Nanotechnological solutions for improving the antibiotic efficiency against biofilms developed by gram-negative bacterial strains. Lett. Appl. Nanobiotechnol., 2013, 2, 97-104.
4. Cotar, A.I.; Grumezescu, A.M.; Andronescu, E.; Voicu, G.; Ficai, A.; Ou, K.L.; Huang, K.S.; Chifiriuc, M.C. Nanotechnological solutions for improving the antibiotic efficiency against biofilms developed by gram-negative bacterial strains. Lett. Appl. Nanobiotechnol., 2013, 2, 97-104.
5. Cotar, A.I.; Chifiriuc, M.C.; Banu, O.; Lazar, V. Molecular characterization of virulence patterns in Pseudomonas aeruginosa strains isolated from respiratory and wound samples. Biointerface. Res. Appl. Chem., 2013, 3, 551-558.
6. Cristea, A.D.; Marutescu, L.; Chifiriuc, M.C.; Lazar, V.; Suciu, I.; Iliescu, A. Antimicrobial susceptibility profiles of bacterial strains isolated from chronic apical periodontitis. Biointerface. Res. Appl. Chem., 2013, 3, 670-675.
7. Srinivasan, A.; Wang, C.; Srivastava, D.K.; Burnette, K.; Shenep, J.L.; Leung, W.; Hayden, R.T. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., 2013, 19, 94-101.
8. Memel, I.A. Infection prevention and control during prolonged human space travel. Clin. Infect. Dis., 2013, 56, 123-130.
9. Daszak, P.; Zambrana-Torrello, C.; Bogich, T.L.; Fernandez, M.; Epstein, J.H.; Murray, K.A.; Hamilton, H. Interdisciplinary approaches to understanding disease emergence: The past, present, and future drivers of Nipah virus emergence. Proc. Natl. Acad. Sci. U. S. A., 2013, 110(Suppl 1), 3681-3688.
10. Cotar, A.I.; Marutescu, L.; Banu, O.; Lazar, V. Antibiotic resistance patterns of Staphylococcus aureus strains isolated from cardiovascular surgery associated infections. Biointerface. Res. Appl. Chem., 2013, 3, 491-497.
11. Marinescu, F.; Marutescu, L.; Chifiriuc, M.C.; Savin, I.; Lazar, V. Virulence markers of Escherichia coli strains isolated from hospital and poultry wastewater. Biointerface. Res. Appl. Chem., 2013, 3, 579-587.
12. Painter, J.A.; Hoekstra, R.M.; Ayers, T.; Tauxe, R.V.; Braden, C.R.; Angulo, F.J.; Griffin, P.M. Attribution of foodborne illnesses, hospitalizations, and deaths to food commodities by using outbreak data, United States, 1998-2008. Emerg. Infect. Dis., 2013, 19, 407-15.
13. Aboutaleb, N.; Kuijper, E.J.; Van Dessel, J.T. Emerging infectious colitis. Curr. Opin Gastroenterol., 2014, 30, 106-115.
14. Persaud, D.; Gay, H.; Ziemniak, C.; Chen, Y.H.; Piatak, M.J.; Chifiriuc, M.C.; Chun, T.W.; Strain, M.; Richman, D.; Luzuriaga, K. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med., 2013, 369, 1828-1835.
15. Munster, V.J.; De Wit, E.; Feldmann, H. Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med., 2013, 368, 1560-1562.
16. Gao, R.; Cao, B.; Hu, Y.; Feng, Z.; Wang, D.; Hu, W.; Chen, J.; Jie, Z.; Qiu, H.; Xu, K.; Xu, X.; Lu, H.; Zhu, W.; Gao, Z.; Xiang, N.; Shen, Y.; He, Z.; Gu, Y.; Zhang, Z.; Yang, Y.; Zhao, X.; Zhou, L.; Li, X.; Zou, S.; Zhang, Y.; Li, X.; Yang, L.; Guo, J.; Dong, J.; Li, Q.; Dong, L.; Zhu, Y.; Bai, T.; Wang, S.; Hao, P.; Yang, W.; Zhang, Y.; Han, J.; Yu, H.; Li, D.; Gao, G.F.; Wu, G.; Wang, Y.; Yuan, Z.; Shu, Y. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med., 2013, 368, 1888-1897.
17. Yetisen, A.K.; Akram, M.S.; Lowe, C.R. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip, 2013, 13, 2210-2251.
18. Vyas, J.M.; Gonzalez, R.G.; Pierce, V.M. Case records of the Massachusetts General Hospital. Case 15-2013. A 76-year-old man with fever, worsening renal function, and altered mental status. N. Engl. J. Med., 2013, 368, 1919-1927.
19. Rock, K.; Brand, S.; Moor, J.; Keeling, M.J. Dynamics of infectious diseases. Rep. Prog. Phys., 2014, 77, 026602.
20. Walmsley, S.L.; Antela, A.; Chmeck, N.; Diuiculescu, D.; Eberhard, A.; Gutiérrez, F.; Hocqueloux, L.; Maggiolo, F.; Sandkovsky, U.; Granier, C.; Pappa, K.; Wynne, B.; Min, S.; Nichols, G. Dolutegravir plus Abacavir–Lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med., 2013, 369, 1807-1818.
21. Mao, J.J.; Chung, A.; Benton, A.; Hill, S.; Uneg, L.; Leonard, C.E.; Hennessey, S.; Holmes, J.H. Online discussion of drug side ef-
[63] Vyasa, H.; Upadhyay, T.; Thakkar, N.; Patel, K.; Upadhyay, U. Nanococcelate: novel bypass of conventional drug delivery system. *Pharma. Tutor*, 2014, 2, 90-97.

[64] Kamboj, S.; Saini, V.; Maggon, N.; Bala, S.; Jhavat, V. Vascular drug delivery systems: a novel approach for drug targeting. *Int. J. Drug Deliver*. 2013, 3, 121-130.

[65] Goudanavar, P.; Manjunatha; Hiremath, D. Development and characterization of perindopril erbumine loaded ethanolic liposomes. *Lett. Appl. Nanobiosci.*, 2014, 3, 151-157.

[66] Tadwee, I.K.; Gore, S.; Giradkar, P. Advances in topical drug delivery system: a review. *Int. J. of Pharm. Res. & All. Sci.*, 2012, 1, 14-23.

[67] Barenholz, Y.C.; Doxil®—the first FDA-approved nano-drug: lessons learned. *J. Control. Release*, 2012, 160, 117-134.

[68] Tomasina, J.; Lheureux, S.; Gauduchon, P.; Rault, S.; Malzert-Deeb, C.; Zhou, X.; Plain, J.; Wiederrecht, G.P.; Bachelot, R. Size dependence of the plasmonic near-field measured via single-targeting a membrane-proximal region of gp41. *Nanoletters*, 2013, 13, 1530-1536.

[69] Chen, J.; Frey, G.; Peng, H.; Rits-Volloch, S.; Garrity, J.; Seaman, L.F.; Biskupek, J.; Kaiser, U.; Lebedev, O.I.; Sildos, I.; Hemmer, P.R.; Konov, V.I.; Gali, A.; Wraithrup, J. Molecular-sized fluorescent nanodiamonds. *Nat. Nanotechnol.*, 2014, 9, 54-58.

[70] Vani, C.; Brindhaha, U.; Annamalai, A. In vivo toxicity assessment of silica nanoparticles in chick embryo. *Lett. Appl. Nanobiosci.*, 2013, 2, 114-119.

[84] Thakor, A.S.; Gambhir, S.S. Nanooncology: the future of cancer diagnosis and therapy. *CA Cancer J. Clin.*, 2013, 63, 395-418.

[85] Lin, X.; Bai, T.; Zuo, Y.Y.; Gu, N. Promote potential applications of nanoparticles as respiratory drug carriers: insights from molecular dynamics simulations. *Nanoscale*, 2014, 6, 2759-2767.

[86] Jin, Y. Multifunctional compact hybrid Au nanoshells: a new generation of nanoplasmic probes for biosensing, imaging, and controlled release. *Acc. Chem. Res.*, 2013, 47, 138-148.

[87] Al-Jamal, K.T. Active drug targeting: lessons learned and new things to consider. *Int. J. Pharm.*, 2013, 454, 525-526.

[88] Shi, P.; Gustafson, J.A.; Mackay, J.A. Genetically engineered nanocarriers for drug delivery. *Int. J. Nanomedicine*, 2014, 9, 1617-1626.

[89] Endsole, A.N.; Ho, R.J. Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. *J. Acquir. Immune Defic. Syndr.*, 2012, 61, 417-424.

[90] Misstear, K.; McNeela, E.A.; Murphy, A.G.; Geoghegan, J.A.; O'Keeffe, K.M.; Fox, J.; Chan, K.; Heuking, S.; Collin, N.; Foster, T.J.; McLaughlin, R.M.; Lavelle, E.C. Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus. *J. Infect. Dis.*, 2014, 209, 1479-1484.

[91] Bakhitiari, S.; Haghani, K.; Basati, G.; Karimfar, M.H. siRNA nanoparticles in the treatment of diseases. *Ther. Deliv.*, 2014, 5, 45-57.

[92] Mei, L.; Lu, Z.; Zhang, W.; Wu, Z.; Zhang, X.; Wang, Y.; Luo, Y.; Li, C.; Jia, Y. Bioconjugated nanoparticles for attachment and penetration into pathogenic bacteria. *Biomaterials*, 2013, 34, 10328-10337.

[93] Daima, H.K.; Selvakannan, P.R.; Kandjani, A.E.; Shukla, R.; Bhargava, S.K.; Bansal, V. Synergistic influence of polyoxometalate surface corona towards enhancing the antibacterial performance of tyrosine-capped Ag nanoparticles. *Nanoscale*, 2014, 6, 758-765.

[94] Rosenthal, J.A.; Chen, L.; Baker, J.L.; Putnam, D.; DeLisa, M.P. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. *Curr. Opin. Biotechnol.*, 2014, 28, 51-58.

[95] Wu, Z.; Chen, K.; Yildiz, I.; Dirksen, A.; Fischer, R.; Dawson, P.E.; Steinmetz, N.F. Development of viral nanoparticles for efficient intracellular delivery. *Nanoscale*, 2012, 4, 3567-3576.

[96] Kesharwani, P.; Jain, K.; Jain, N.K. Dendrimer as nanocarrier for drug delivery. *Prog. Polym. Sci.*, 2014, 39, 268-307.

[97] Tian, W.D.; Ma, Y.Q. Theoretical and computational studies of dendrimers as delivery vectors. *Chem. Soc. Rev.*, 2013, 42, 705-727.

[98] Namazkar, S.; Endoud, S.; Asadollahi, Z. Synthesis of poly(aminodiame)-dendrimer-silver nanoparticles composite for application as bactericides. *Biointerface. Res. Appl. Chem.*, 2014, 4, 704-711.

[99] Lo, S.T.; Kumar, A.; Hsieh, J.T.; Sun, X. Dendrimer nanocapsoids for potential theranostics of prostate cancer with a focus on radio-chemistry. *Mol. Pharm.*, 2013, 10, 793-812.

[100] Berzi, A.; Varga, N.; Sattin, S.; Antonazzo, P.; Biasin, M.; Cetin, I.; Trabattoni, D.; Bernardi, A.; Clerici, M. Pseudo-mannosylated DC-SIGN ligands as potential adjuvants for HIV vaccines. *Viruses*, 2014, 6, 391-403.

[101] Varga, N.; Sutkevicite, I.; Ribeiro-Viania, R.; Berzi, A.; Ramdasi, R.; Daghetti, A.; Vettoretti, G.; Amara, A.; Clerici, M.; Rojo, J.; Fieschi, F.; Bernardi, A. A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and Dengue virus. *Biomaterials*, 2014, 35, 4175-4184.

[102] Pedziwiatr-Werbicka, E.; Fuentes, E.; Dzmitruk, V.; Sanchez-Nieves, J.; Sadas, M.; Drozd, E.; Skhahbaza, A.; Shcharbin, D.; De La Mata, F.J.; Gomez-Ramirez, R.; Munoz-Fernandez, M.A.; Bryszewska, M. Novel Si-C carbohydrates dendrimers as carriers for anti-HIV nucleic acids: studies on complexation and interaction with blood cells. *Colloids Surf. B. Biointerfaces*, 2013, 109, 183-189.
Active Targeted Drug Delivery for Microbes Using Nano-Carriers

[104] Reymond, J.L.; Bergmann, M.; Darbre, T. Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors. *Chem. Soc. Rev.*, 2013, 42, 4814-22.

[105] Kadam, R.U.; Bergmann, M.; Garg, D.; Gabrieli, G.; Stocker, A.; Darbre, T.; Reymond, J.L. Structure-based optimization of the terminal tripeptide in glycopeptide dendrimer inhibitors of Pseudomonas aeruginosa biofilms targeting LecA. *Chemistry*, 2013, 19, 17054-17063.

[106] Kambhampati, S.P.; Kannan, R.M. Dendrimer nanoparticles for ocular drug delivery. *J. Ocul. Pharmacol. Ther.*, 2013, 29, 151-165.

[107] Bahar, A.A.; Ren, D. Antimicrobial peptides. *Pharmaceuticals*, 2013, 6, 1543-75.

[108] De Volder, M.F.; Tawfick, S.H.; Baughman, R.H.; Hart, A.J. Carbon nanotubes: present and future commercial applications. *Science*, 2013, 339, 535-539.

[109] Jia, Y.; Yu, K.; Qian, K. Facile approach to prepare multi-walled carbon nanotubes/graphene nanoplatelets hybrid materials. *Nanoscale Res. Lett.*, 2013, 8, 1-6.

[110] Moore, T.L.; Pitzer, J.E.; Podila, R.; Wang, X.; Lewis, R.L.; Grimes, S.W.; Wilson, J.R.; Skjervold, E.; Brown, J.M.; Rao, A.; Alexis, F. Multifunctional polymer-coated carbon nanotubes for safe drug delivery. *Part. Part. Syst. Char.*, 2013, 30, 365-373.

[111] Mehra, N.K.; Mishra, V.; Jain, N.K. A review of ligand tethered surface engineered carbon nanotubes. *Biomaterials*, 2014, 35, 1267-1283.

[112] Lehner, R.; Wang, X.; Marsch, S.; Hunziker, P. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. *Nanomedicine*, 2013, 9, 742-757.

[113] Nirosa, T.; Roy, A. Carbon nanotubes—a nanotechnology based drug delivery system and its recent trends: a review. *Carbon*, 2013, 5, 1765-1768.

[114] Bates, K.; Kostarelos, K. Carbon nanotubes as vectors for gene therapy: past achievements, present challenges and future goals. *Adv. Drug Deliv. Rev.*, 2013, 65, 2023-2033.

[115] Sanket, T.; Shiv, G.; Pramod, S.; Ajay, P. Carbon nanotubes in pharmaceutical nanotechnology: an introduction to future drug delivery system. *Indo Am. J. Pharm. Res.*, 2013, 3, 3512-3534.

[116] Fadel, T.R.; Fahmy, T.M. Immunotherapy applications of carbon nanotubes: from design to safe applications. *Trends Biotechnol.*, 2014, 32, 196-209.

[117] Couvreur, P. Nanoparticles in drug delivery: past, present and future. *Adv. Drug Deliv. Rev.*, 2013, 65, 21-23.